Clinical Trial Results:
A Phase 2, Multicentre, Randomised, Open-Label, Parallel Group Study to Evaluate
the Safety and Efficacy of VELCADE® in combination with Dexamethasone or
VELCADE® in combination with Dexamethasone and Cyclophosphamide or
VELCADE® in combination with Dexamethasone and Lenalidomide in Subjects
with Multiple Myeloma who are Refractory to or Have Relapsed / progressed after
Primary Therapy for Multiple Myeloma and have achieved stable disease after 4
cycles of VELCADE®/Dexamethasone therapy
Summary
|
|
EudraCT number |
2007-001462-33 |
Trial protocol |
FR LT HU ES GR GB DE |
Global completion date |
02 Aug 2011
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
05 Jun 2016
|
First version publication date |
05 Jun 2016
|
Other versions |
|
Summary report(s) |
26866138MMY2045_(2007-001462-33)_(bortezomib)_CT.gov Results |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.